My view is always to partner with a well established distributor they could provide upfront and milestone payments to fund the DurAVR and delivery products to commercialisation. In return, the partner got exclusive rights and guaranteed margin say 15% of sales over a fixed term with option to renew.
I see selling the company short with the unmatched technology and the groundbreaking tissue science product having even greater potential for many more emerging new products potential. I see ADAPT could be worth much more than DurAVR and that was the tissue science got me invested over 3 years ago.
if SIO, Mercer and the top shareholders share the same opinion, we could well be another CSL in the making.
DYOR!
AVR Price at posting:
$9.40 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)